UBS Maintains Buy on Medline, Lowers Price Target to $43
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.
Stocks · News reference
TD Cowen Maintains Buy on Medline, Lowers Price Target to $45
TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.
BTIG Reiterates Buy on Medline, Maintains $55 Price Target
BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.
Reported Earlier, FDA Says Medline Issued Correction For Convenience Kits Containing B. Braun Bupivacaine Hydrochloride Components, Identified As Most Serious Recall Type; B. Braun Reported 35 Serious Injuries, No Deaths
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-medline-issues-correction-convenience-kits-containing-b-braun-bupivacaine